Plant Name: Leucas volkensii
Taxonomic Information:
Plant ID: NPO26674
Plant Latin Name: Leucas volkensii
Taxonomy Genus: Leucas
Taxonomy Family: Lamiaceae
Plant External Links:
NCBI TaxonomyDB:
483847
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2C; HRH3; ADRA2A; | |
| TSHR; | |
| TDP1; | |
| PPARA; | |
| TLR2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | HRH3 | Histamine H3 receptor | Q9Y5N1 | CHEMBL264 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0065007; biological regulation | GO:0045761; regulation of adenylate cyclase activity | 4.108E-07 | 1.531E-03 | ADRA2A, HRH3, TSHR |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 6.752E-07 | 1.531E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 6.752E-07 | 1.531E-03 | ADRA2A, ADRA2C |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 3.377E-07 | 1.531E-03 | ADRA2A, ADRA2C |
| MF | GO:0060089; molecular transducer activity | GO:0038023; signaling receptor activity | 8.541E-07 | 1.531E-03 | ADRA2A, ADRA2C, HRH3, PPARA, TLR2, TSHR |
| BP | GO:0009987; cellular process | GO:0007189; adenylate cyclase-activating G-protein coupled receptor signaling pathway | 1.720E-06 | 1.824E-03 | ADRA2A, ADRA2C, TSHR |
| MF | Unclassified; | GO:0004872; receptor activity | 1.759E-06 | 1.824E-03 | ADRA2A, ADRA2C, HRH3, PPARA, TLR2, TSHR |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 3.149E-06 | 2.637E-03 | ADRA2A, ADRA2C |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 3.149E-06 | 2.637E-03 | ADRA2A, ADRA2C |
| MF | GO:0005488; binding | GO:0031690; adrenergic receptor binding | 1.718E-05 | 9.590E-03 | ADRA2A, ADRA2C |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 3.803E-05 | 1.840E-02 | ADRA2A, ADRA2C, HRH3, TLR2, TSHR |
| CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 1.529E-04 | 4.498E-02 | ADRA2A, TLR2, TSHR |
| CC | GO:0044456; synapse part | GO:0098793; presynapse | 1.499E-03 | 2.190E-01 | ADRA2C, HRH3 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.876E-03 | 2.522E-01 | ADRA2A, TSHR |
| CC | Unclassified; | GO:0106003; amyloid-beta complex | 3.980E-03 | 3.994E-01 | TLR2 |
| CC | GO:0044464; cell part | GO:0009986; cell surface | 1.503E-02 | 9.173E-01 | TLR2, TSHR |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.220E-06 | 3.415E-05 | HRH3, ADRA2C, ADRA2A, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 1.416E-03 | 1.868E-02 | ADRA2C, ADRA2A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 2.002E-03 | 1.868E-02 | PPARA, TSHR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 2.528E-02 | 5.839E-02 | TLR2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 2.391E-02 | 5.839E-02 | PPARA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04922 | Glucagon signaling pathway | 3.482E-02 | 5.839E-02 | PPARA |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 3.448E-02 | 5.839E-02 | TLR2 |
| 09160 Human Diseases | 09162 Immune diseases | hsa05323 | Rheumatoid arthritis | 3.108E-02 | 5.839E-02 | TLR2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 3.584E-02 | 5.839E-02 | TLR2 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 3.754E-02 | 5.839E-02 | PPARA |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA2C; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2A; ADRA2C; HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HRH3; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | HRH3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Excessive daytime sleepiness | F51.1, G47.1 | HRH3; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obese insulin-resistant disorders | E11 | HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; HRH3; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C; HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HRH3; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HRH3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Narcolepsy | G47.4 | HRH3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HRH3; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; HRH3; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
